Does the media refer more to GENB or ALT?

In the previous week, Generate Biomedicines had 1 more articles in the media than Altimmune. MarketBeat recorded 2 mentions for Generate Biomedicines and 1 mentions for Altimmune. Altimmune's average media sentiment score of 0.72 beat Generate Biomedicines' score of 0.47 indicating that Altimmune is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Generate Biomedicines 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Altimmune 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to OCUL or ALT?

In the previous week, Ocular Therapeutix had 1 more articles in the media than Altimmune. MarketBeat recorded 2 mentions for Ocular Therapeutix and 1 mentions for Altimmune. Ocular Therapeutix's average media sentiment score of 1.14 beat Altimmune's score of 0.72 indicating that Ocular Therapeutix is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Ocular Therapeutix 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Altimmune 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to ALT or PVLA?

In the previous week, Palvella Therapeutics had 5 more articles in the media than Altimmune. MarketBeat recorded 6 mentions for Palvella Therapeutics and 1 mentions for Altimmune. Altimmune's average media sentiment score of 0.72 beat Palvella Therapeutics' score of 0.70 indicating that Altimmune is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Altimmune 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Palvella Therapeutics 2 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts rate NNNN or ALT?

Altimmune has a consensus target price of $15.71, indicating a potential upside of 397.29%. Given Altimmune's stronger consensus rating and higher probable upside, analysts plainly believe Altimmune is more favorable than Anbio Biotechnology. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Anbio Biotechnology 0 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00 Altimmune 2 Sell rating(s) 1 Hold rating(s) 8 Buy rating(s) 0 Strong Buy rating(s) 2.55

Which has preferable valuation and earnings, NNNN or ALT?

Anbio Biotechnology has higher revenue and earnings than Altimmune. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Anbio Biotechnology $8.65M 211.26 $6.40M N/A N/A Altimmune $40K 15,363.13 -$88.09M -$0.93 N/A

Which has higher earnings & valuation, PGEN or ALT?

Altimmune has lower revenue, but higher earnings than Precigen. Precigen is trading at a lower price-to-earnings ratio than Altimmune, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Precigen $9.68M 207.72 -$250.64M -$1.18 N/A Altimmune $40K 15,363.13 -$88.09M -$0.93 N/A

Is PGEN or ALT more profitable?

Precigen has a net margin of -646.99% compared to Altimmune's net margin of -214,860.98%. Precigen's return on equity of 717.50% beat Altimmune's return on equity. Company Net Margins Return on Equity Return on Assets Precigen -646.99% 717.50% 58.48% Altimmune -214,860.98% -42.57% -35.57%

Does the media favor PGEN or ALT?

In the previous week, Precigen had 7 more articles in the media than Altimmune. MarketBeat recorded 8 mentions for Precigen and 1 mentions for Altimmune. Altimmune's average media sentiment score of 0.72 beat Precigen's score of -0.15 indicating that Altimmune is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Precigen 4 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Altimmune 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Altimmune (ALT) Competitors

$3.16 +0.01 (+0.32%)

Closing price 04:00 PM Eastern

Extended Trading

$3.18 +0.02 (+0.54%)

As of 07:58 PM Eastern

Compare

ALT vs. GENB, OCUL, PVLA, NNNN, and PGEN

Should you buy Altimmune stock or one of its competitors? MarketBeat compares Altimmune with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Altimmune include Generate Biomedicines (GENB), Ocular Therapeutix (OCUL), Palvella Therapeutics (PVLA), Anbio Biotechnology (NNNN), and Precigen (PGEN). These companies are all part of the "pharmaceutical products" industry.

How does Altimmune compare to Generate Biomedicines?

Generate Biomedicines (NASDAQ:GENB) and Altimmune (NASDAQ:ALT) are both pharmaceutical products companies, but which is the superior business? We will contrast the two businesses based on the strength of their media sentiment, risk, institutional ownership, valuation, profitability, earnings, analyst recommendations and dividends.

Generate Biomedicines has a net margin of 0.00% compared to Altimmune's net margin of -214,860.98%. Generate Biomedicines' return on equity of 0.00% beat Altimmune's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Generate Biomedicines	N/A	N/A	N/A
Altimmune	-214,860.98%	-42.57%	-35.57%

Altimmune has lower revenue, but higher earnings than Generate Biomedicines. Generate Biomedicines is trading at a lower price-to-earnings ratio than Altimmune, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Generate Biomedicines	$30.30M	73.66	-$137.17M	-$1.07	N/A
Altimmune	$40K	15,363.13	-$88.09M	-$0.93	N/A

Generate Biomedicines presently has a consensus target price of $25.40, suggesting a potential upside of 45.89%. Altimmune has a consensus target price of $15.71, suggesting a potential upside of 397.29%. Given Altimmune's higher possible upside, analysts plainly believe Altimmune is more favorable than Generate Biomedicines.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Generate Biomedicines	0 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.86
Altimmune	2 Sell rating(s)	1 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.55

In the previous week, Generate Biomedicines had 1 more articles in the media than Altimmune. MarketBeat recorded 2 mentions for Generate Biomedicines and 1 mentions for Altimmune. Altimmune's average media sentiment score of 0.72 beat Generate Biomedicines' score of 0.47 indicating that Altimmune is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Generate Biomedicines	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Altimmune	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

78.1% of Altimmune shares are owned by institutional investors. 1.6% of Altimmune shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Summary

Altimmune beats Generate Biomedicines on 9 of the 15 factors compared between the two stocks.

How does Altimmune compare to Ocular Therapeutix?

Ocular Therapeutix (NASDAQ:OCUL) and Altimmune (NASDAQ:ALT) are both medical companies, but which is the better business? We will compare the two companies based on the strength of their dividends, media sentiment, institutional ownership, profitability, earnings, analyst recommendations, valuation and risk.

Ocular Therapeutix has a net margin of -558.24% compared to Altimmune's net margin of -214,860.98%. Altimmune's return on equity of -42.57% beat Ocular Therapeutix's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Ocular Therapeutix	-558.24%	-64.28%	-48.15%
Altimmune	-214,860.98%	-42.57%	-35.57%

Ocular Therapeutix has a beta of 0.88, indicating that its stock price is 12% less volatile than the broader market. Comparatively, Altimmune has a beta of 0.25, indicating that its stock price is 75% less volatile than the broader market.

59.2% of Ocular Therapeutix shares are owned by institutional investors. Comparatively, 78.1% of Altimmune shares are owned by institutional investors. 3.1% of Ocular Therapeutix shares are owned by insiders. Comparatively, 1.6% of Altimmune shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Altimmune has lower revenue, but higher earnings than Ocular Therapeutix. Ocular Therapeutix is trading at a lower price-to-earnings ratio than Altimmune, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Ocular Therapeutix	$51.95M	40.63	-$265.94M	-$1.46	N/A
Altimmune	$40K	15,363.13	-$88.09M	-$0.93	N/A

Ocular Therapeutix currently has a consensus target price of $25.11, suggesting a potential upside of 160.49%. Altimmune has a consensus target price of $15.71, suggesting a potential upside of 397.29%. Given Altimmune's higher possible upside, analysts clearly believe Altimmune is more favorable than Ocular Therapeutix.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Ocular Therapeutix	1 Sell rating(s)	1 Hold rating(s)	12 Buy rating(s)	0 Strong Buy rating(s)	2.79
Altimmune	2 Sell rating(s)	1 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.55

In the previous week, Ocular Therapeutix had 1 more articles in the media than Altimmune. MarketBeat recorded 2 mentions for Ocular Therapeutix and 1 mentions for Altimmune. Ocular Therapeutix's average media sentiment score of 1.14 beat Altimmune's score of 0.72 indicating that Ocular Therapeutix is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Ocular Therapeutix	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Altimmune	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Ocular Therapeutix and Altimmune tied by winning 8 of the 16 factors compared between the two stocks.

How does Altimmune compare to Palvella Therapeutics?

Altimmune (NASDAQ:ALT) and Palvella Therapeutics (NASDAQ:PVLA) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their media sentiment, institutional ownership, profitability, dividends, valuation, earnings, risk and analyst recommendations.

Palvella Therapeutics has higher revenue and earnings than Altimmune. Palvella Therapeutics is trading at a lower price-to-earnings ratio than Altimmune, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Altimmune	$40K	15,363.13	-$88.09M	-$0.93	N/A
Palvella Therapeutics	$42.81M	49.16	-$41.72M	-$4.17	N/A

In the previous week, Palvella Therapeutics had 5 more articles in the media than Altimmune. MarketBeat recorded 6 mentions for Palvella Therapeutics and 1 mentions for Altimmune. Altimmune's average media sentiment score of 0.72 beat Palvella Therapeutics' score of 0.70 indicating that Altimmune is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Altimmune	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Palvella Therapeutics	2 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

78.1% of Altimmune shares are held by institutional investors. Comparatively, 40.1% of Palvella Therapeutics shares are held by institutional investors. 1.6% of Altimmune shares are held by company insiders. Comparatively, 17.2% of Palvella Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Altimmune currently has a consensus target price of $15.71, suggesting a potential upside of 397.29%. Palvella Therapeutics has a consensus target price of $199.53, suggesting a potential upside of 35.96%. Given Altimmune's higher probable upside, equities analysts clearly believe Altimmune is more favorable than Palvella Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Altimmune	2 Sell rating(s)	1 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.55
Palvella Therapeutics	1 Sell rating(s)	0 Hold rating(s)	14 Buy rating(s)	1 Strong Buy rating(s)	2.94

Altimmune has a beta of 0.25, indicating that its share price is 75% less volatile than the broader market. Comparatively, Palvella Therapeutics has a beta of -0.2, indicating that its share price is 120% less volatile than the broader market.

Palvella Therapeutics has a net margin of 0.00% compared to Altimmune's net margin of -214,860.98%. Altimmune's return on equity of -42.57% beat Palvella Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Altimmune	-214,860.98%	-42.57%	-35.57%
Palvella Therapeutics	N/A	-56.87%	-42.50%

Summary

Altimmune beats Palvella Therapeutics on 9 of the 17 factors compared between the two stocks.

How does Altimmune compare to Anbio Biotechnology?

Anbio Biotechnology (NASDAQ:NNNN) and Altimmune (NASDAQ:ALT) are both small-cap pharmaceutical products companies, but which is the better stock? We will contrast the two businesses based on the strength of their earnings, dividends, profitability, analyst recommendations, institutional ownership, media sentiment, risk and valuation.

Altimmune has a consensus target price of $15.71, indicating a potential upside of 397.29%. Given Altimmune's stronger consensus rating and higher probable upside, analysts plainly believe Altimmune is more favorable than Anbio Biotechnology.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Anbio Biotechnology	0 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	2.00
Altimmune	2 Sell rating(s)	1 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.55

Anbio Biotechnology has a net margin of 0.00% compared to Altimmune's net margin of -214,860.98%. Anbio Biotechnology's return on equity of 0.00% beat Altimmune's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Anbio Biotechnology	N/A	N/A	N/A
Altimmune	-214,860.98%	-42.57%	-35.57%

Anbio Biotechnology has a beta of 5.15, indicating that its stock price is 415% more volatile than the broader market. Comparatively, Altimmune has a beta of 0.25, indicating that its stock price is 75% less volatile than the broader market.

In the previous week, Altimmune had 1 more articles in the media than Anbio Biotechnology. MarketBeat recorded 1 mentions for Altimmune and 0 mentions for Anbio Biotechnology. Anbio Biotechnology's average media sentiment score of 1.87 beat Altimmune's score of 0.72 indicating that Anbio Biotechnology is being referred to more favorably in the media.

Company	Overall Sentiment
Anbio Biotechnology	Very Positive
Altimmune	Positive

78.1% of Altimmune shares are held by institutional investors. 1.6% of Altimmune shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Anbio Biotechnology has higher revenue and earnings than Altimmune.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Anbio Biotechnology	$8.65M	211.26	$6.40M	N/A	N/A
Altimmune	$40K	15,363.13	-$88.09M	-$0.93	N/A

Summary

Anbio Biotechnology and Altimmune tied by winning 7 of the 14 factors compared between the two stocks.

How does Altimmune compare to Precigen?

Precigen (NASDAQ:PGEN) and Altimmune (NASDAQ:ALT) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their earnings, dividends, media sentiment, risk, valuation, profitability, analyst recommendations and institutional ownership.

Altimmune has lower revenue, but higher earnings than Precigen. Precigen is trading at a lower price-to-earnings ratio than Altimmune, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Precigen	$9.68M	207.72	-$250.64M	-$1.18	N/A
Altimmune	$40K	15,363.13	-$88.09M	-$0.93	N/A

33.5% of Precigen shares are owned by institutional investors. Comparatively, 78.1% of Altimmune shares are owned by institutional investors. 41.4% of Precigen shares are owned by insiders. Comparatively, 1.6% of Altimmune shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Precigen has a beta of 1, indicating that its share price has a similar volatility profile to the broader market.Comparatively, Altimmune has a beta of 0.25, indicating that its share price is 75% less volatile than the broader market.

Precigen presently has a consensus price target of $12.50, suggesting a potential upside of 121.63%. Altimmune has a consensus price target of $15.71, suggesting a potential upside of 397.29%. Given Altimmune's stronger consensus rating and higher possible upside, analysts clearly believe Altimmune is more favorable than Precigen.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Precigen	1 Sell rating(s)	2 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.33
Altimmune	2 Sell rating(s)	1 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.55

Precigen has a net margin of -646.99% compared to Altimmune's net margin of -214,860.98%. Precigen's return on equity of 717.50% beat Altimmune's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Precigen	-646.99%	717.50%	58.48%
Altimmune	-214,860.98%	-42.57%	-35.57%

In the previous week, Precigen had 7 more articles in the media than Altimmune. MarketBeat recorded 8 mentions for Precigen and 1 mentions for Altimmune. Altimmune's average media sentiment score of 0.72 beat Precigen's score of -0.15 indicating that Altimmune is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Precigen	4 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Altimmune	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Altimmune beats Precigen on 9 of the 16 factors compared between the two stocks.

Get Altimmune News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ALT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ALT vs. The Competition

Export

Metric	Altimmune	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$612.59M	$3.02B	$6.82B	$12.56B
Dividend Yield	N/A	2.02%	2.68%	6.64%
P/E Ratio	-3.40	20.06	27.94	24.55
Price / Sales	15,363.13	359.51	534.91	98.43
Price / Cash	N/A	57.28	48.59	58.15
Price / Book	1.59	4.32	10.91	6.45
Net Income	-$88.09M	$64.45M	$3.57B	$336.71M
7 Day Performance	10.10%	5.12%	3.62%	2.55%
1 Month Performance	8.97%	5.32%	4.40%	0.32%
1 Year Performance	-35.51%	30.23%	35.81%	25.76%

Altimmune Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ALT Altimmune	2.0725 of 5 stars	$3.16 +0.3%	$15.71 +397.3%	-25.5%	$612.59M	$40K	N/A	50
GENB Generate Biomedicines	2.5105 of 5 stars	$16.91 +2.7%	$25.40 +50.2%	N/A	$2.17B	$30.30M	N/A	312	High Trading Volume
OCUL Ocular Therapeutix	3.1186 of 5 stars	$9.90 +0.6%	$25.11 +153.6%	+4.1%	$2.15B	$51.95M	N/A	230	News Coverage
PVLA Palvella Therapeutics	2.819 of 5 stars	$154.84 +4.5%	$199.53 +28.9%	+509.9%	$2.13B	$42.81M	N/A	N/A	Analyst Forecast
NNNN Anbio Biotechnology	0.9081 of 5 stars	$13.55 -6.7%	N/A	N/A	$2.09B	$8.65M	N/A	27	Positive News

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:ALT) was last updated on 7/2/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Altimmune (ALT) Competitors

ALT vs. GENB, OCUL, PVLA, NNNN, and PGEN

How does Altimmune compare to Generate Biomedicines?

Summary

How does Altimmune compare to Ocular Therapeutix?

Summary

How does Altimmune compare to Palvella Therapeutics?

Summary

How does Altimmune compare to Anbio Biotechnology?

Summary

How does Altimmune compare to Precigen?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ALT vs. The Competition

Altimmune Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Altimmune (ALT) Competitors

ALT vs. GENB, OCUL, PVLA, NNNN, and PGEN

How does Altimmune compare to Generate Biomedicines?

Is GENB or ALT more profitable?

Which has stronger earnings & valuation, GENB or ALT?

Do analysts rate GENB or ALT?

Does the media refer more to GENB or ALT?

Do institutionals & insiders have more ownership in GENB or ALT?

Summary

How does Altimmune compare to Ocular Therapeutix?

Is OCUL or ALT more profitable?

Which has more risk and volatility, OCUL or ALT?

Do insiders and institutionals have more ownership in OCUL or ALT?

Which has higher valuation and earnings, OCUL or ALT?

Do analysts recommend OCUL or ALT?

Does the media refer more to OCUL or ALT?

Summary

How does Altimmune compare to Palvella Therapeutics?

Which has stronger valuation & earnings, ALT or PVLA?

Does the media refer more to ALT or PVLA?

Do insiders and institutionals have more ownership in ALT or PVLA?

Do analysts recommend ALT or PVLA?

Which has more volatility & risk, ALT or PVLA?

Is ALT or PVLA more profitable?

Summary

How does Altimmune compare to Anbio Biotechnology?

Do analysts rate NNNN or ALT?

Is NNNN or ALT more profitable?

Which has more volatility & risk, NNNN or ALT?

Does the media prefer NNNN or ALT?

Do insiders & institutionals believe in NNNN or ALT?

Which has preferable valuation and earnings, NNNN or ALT?

Summary

How does Altimmune compare to Precigen?

Which has higher earnings & valuation, PGEN or ALT?

Do insiders & institutionals hold more shares of PGEN or ALT?

Which has more risk & volatility, PGEN or ALT?

Do analysts rate PGEN or ALT?

Is PGEN or ALT more profitable?

Does the media favor PGEN or ALT?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ALT vs. The Competition

Altimmune Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools